Tag: Bendamustine
Polatuzumab Vedotin Demonstrates Clinical Efficacy Across a Range of Diffuse Large...
Polatuzumab vedotin (DCDS4501A), a novel, targeted anti-cancer agent being developed by Genentech/Roche, is a first-in-class anti-CD79b antibody-drug conjugate or ADC currently being investigated for...
Updates from the 14th International Conference on Malignant Lymphoma (ICML)
Since the inaugurational meeting in 1981, the International Conference on Malignant Lymphoma (ICML), traditionally takes place in Lugano, Switzerland, has become one of the...
Brentuximab Vedotin Identified as Potentially Transformational in Hodgkin’s lymphoma Treament
Earlier this month, during the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), held in Orlando, Florida from December 5–8,...
Trial Shows 92% Objective Response Rate in the Evaluation of Brentuximab...
Data presented at the 2014 Annual Bone Marrow Transplant (BMT) Tandem Meetings organized by The American Society for Blood and Marrow Transplantation and the Center for International Blood & Marrow Transplant Research being held in Grapevine (Dallas), Texas, February 26 - March 2, 2014, highlights the benefits of brentuximab vedotin (Adcetris®; Seattle Genetics) in various treatment schedules for hard to treat cancers.
